Current opinions for the management of asthma associated with ear, nose and throat comorbidities

Eur Respir Rev. 2018 Nov 21;27(150):180056. doi: 10.1183/16000617.0056-2018. Print 2018 Dec 31.

Abstract

Ear, nose and throat (ENT) comorbidities are common in patients with asthma and are frequently associated with poorer asthma outcomes. All these comorbidities are "treatable traits" in asthma. Identification and management of these disorders may spare medication usage and contribute to improved asthma control and quality of life, and a decrease in exacerbation rates.This review summarises recent data about the prevalence, clinical impact and treatment effects of ENT comorbidities in asthma including allergic rhinitis, chronic rhinosinusitis with and without nasal polyposis, aspirin-exacerbated respiratory disease, obstructive sleep apnoea and vocal cord dysfunction.Many of these comorbidities are possible to be managed by the pulmonologist, but the collaboration with the ENT specialist is essential for patients with chronic rhinosinusitis or vocal cord dysfunction. Further rigorous research is needed to study the efficacy of comorbidity treatment to improve asthma outcomes, in particular with the development of biotherapies in severe asthma that can also be beneficial in some ENT diseases.

Publication types

  • Review

MeSH terms

  • Anti-Asthmatic Agents / adverse effects
  • Anti-Asthmatic Agents / therapeutic use*
  • Asthma / diagnosis
  • Asthma / drug therapy*
  • Asthma / epidemiology
  • Asthma / physiopathology
  • Comorbidity
  • Disease Progression
  • Ear Diseases / diagnosis
  • Ear Diseases / epidemiology
  • Ear Diseases / physiopathology
  • Ear Diseases / therapy*
  • Health Status
  • Humans
  • Lung / drug effects*
  • Lung / physiopathology
  • Nose Diseases / diagnosis
  • Nose Diseases / epidemiology
  • Nose Diseases / physiopathology
  • Nose Diseases / therapy*
  • Pharyngeal Diseases / diagnosis
  • Pharyngeal Diseases / epidemiology
  • Pharyngeal Diseases / physiopathology
  • Pharyngeal Diseases / therapy*
  • Quality of Life
  • Remission Induction
  • Risk Factors
  • Treatment Outcome

Substances

  • Anti-Asthmatic Agents